CGLAS: Results of cost-effectiveness analysis, treatment based on assignment and compliance.</p
Cost-effectiveness output for the DCRSHP test = £465.48 using the outcome of the QALY.</p
Results for the two primary outcomes per protocol and intention-to-treat analysis.</p
CGAAS: CERs under scale-up scenarios as a share of CERs of original programme.</p
<p>Cost-effectiveness analysis results for complete case and sensitivity analyses.</p
Results of the main cost-effectiveness analysis of three different DAA treatment scenarios.</p
CGLAS: Summary of costs of the paralegal programme, by year, location, and category.</p
CGAAS: Cost-effectiveness in increasing SLM practice adoption, under scale-up scenarios.</p
Cost-effectiveness finding of KRAS testing for corresponding targeted therapies.</p
<p>Results of the cost effectiveness analysis according to incremental cost effectiveness ratio (ICE...
<p>Results of the base-case cost-effectiveness analysis and the probabilistic sensitivity analysis.<...
Primary study characteristics and conclusions of cost-effectiveness analyses.</p
<p>Results of sensitivity analyses which altered cost-effective intervention.</p
Cost-effectiveness finding of RAS testing for corresponding targeted therapies.</p
<p>Costs and outcomes for the most cost-effective (cost saving) interventions.</p
Cost-effectiveness plane in incremental number of treatment success and incremental cost.</p
Cost-effectiveness output for the DCRSHP test = £465.48 using the outcome of the QALY.</p
Results for the two primary outcomes per protocol and intention-to-treat analysis.</p
CGAAS: CERs under scale-up scenarios as a share of CERs of original programme.</p
<p>Cost-effectiveness analysis results for complete case and sensitivity analyses.</p
Results of the main cost-effectiveness analysis of three different DAA treatment scenarios.</p
CGLAS: Summary of costs of the paralegal programme, by year, location, and category.</p
CGAAS: Cost-effectiveness in increasing SLM practice adoption, under scale-up scenarios.</p
Cost-effectiveness finding of KRAS testing for corresponding targeted therapies.</p
<p>Results of the cost effectiveness analysis according to incremental cost effectiveness ratio (ICE...
<p>Results of the base-case cost-effectiveness analysis and the probabilistic sensitivity analysis.<...
Primary study characteristics and conclusions of cost-effectiveness analyses.</p
<p>Results of sensitivity analyses which altered cost-effective intervention.</p
Cost-effectiveness finding of RAS testing for corresponding targeted therapies.</p
<p>Costs and outcomes for the most cost-effective (cost saving) interventions.</p
Cost-effectiveness plane in incremental number of treatment success and incremental cost.</p
Cost-effectiveness output for the DCRSHP test = £465.48 using the outcome of the QALY.</p
Results for the two primary outcomes per protocol and intention-to-treat analysis.</p
CGAAS: CERs under scale-up scenarios as a share of CERs of original programme.</p
DOI
Add to ORKG